Prophylactic ultra-low dose rituximab to maintain remission in relapsing adult minimal change disease.

Authors:
Leung WY; Wu HHL; Woywodt A; Ponnusamy A.

Journal:
Clin Kidney J

Publication Year: 2023

DOI:
10.1093/ckj/sfad270

PMCID:
PMC10768774

PMID:
38186892

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Clin Kidney J

Abbreviation: Clin Kidney J

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Urology & Nephrology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Actioning the findings of hard endpoint clinical trials as they emerge in the realm of chronic kidn…
Strippoli GFM; Green SC. (2024) - Transparency Score: 2/6
Anticoagulation in patients with end-stage kidney disease and atrial fibrillation: a national popul…
Kim DG; Kim SH; Park SY and 5 more (2024) - Transparency Score: 2/6
Characterization of glomerular basement membrane components within pediatric glomerular diseases.
Chen D; Zhou X; Gan C and 11 more (2024) - Transparency Score: 3/6
Dapagliflozin in chronic kidney disease: cost-effectiveness beyond the DAPA-CKD trial.
McEwan P; Davis JA; Gabb PD and 7 more (2024) - Transparency Score: 3/6
Elimination and penetration of amikacin into urine in patients with decreased glomerular filtration…
Hartinger JM; Dvořáčková E; Krátký V and 11 more (2024) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"CONFLICT OF INTEREST STATEMENT A.W. is member of the CKJ Editorial Board. The other authors have no disclosures or conflicts of interest to declare for this manuscript. There is no external funding received for this manuscript."

Evidence found in paper:

"CONFLICT OF INTEREST STATEMENT: A.W. is member of the CKJ Editorial Board. The other authors have no disclosures or conflicts of interest to declare for this manuscript. There is no external funding received for this manuscript."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025